GILEAD SCIENCES, INC. (GILD) — Fundamental Analysis

Gilead Sciences is a large-cap biopharmaceutical company best known for its dominant HIV and antiviral franchises, and the numbers tell a story of a mature but resilient business finding its footing again. After a turbulent 2024 — when a large acquisition-related impairment charge crushed reported profits — the company bounced back strongly in 2025, posting nearly $29.4 billion in revenue and returning to double-digit net margins. The most recent quarter (Q1 2026) is even more encouraging, with margins running above 29% and debt levels declining. Revenue growth has been modest in recent years, around 2.6% annually over three years and 3.6% over five, reflecting Gilead's reliance on established blockbuster drugs and the slow build of its oncology pipeline. Capital spending is lean and stable, confirming this is a cash-generating machine rather than a heavy industrial reinvestor. On balance, Gilead looks financially sound: improving profitability, manageable leverage, and a business model that throws off substantial cash — though investors will be watching the oncology pipeline closely for the next leg of growth.

Snapshot & Big Picture

Gilead Sciences has operated at a revenue scale of roughly $22–$30 billion for the better part of a decade, with its HIV franchise (Biktarvy, Descovy) providing a durable revenue floor. The company's peak revenue years were 2016–2017, when its hepatitis C drugs (Harvoni, Sovaldi) were at their commercial zenith. Since then, revenue stabilized at a lower but still massive level. The 2020 acquisition of Immunomedics and 2023 acquisition of CymaBay and other oncology/inflammation assets have broadened the pipeline, though impairment charges from these deals have periodically weighed on reported earnings. The core business generates strong operating cash flow, and management has been steadily paying down the elevated debt taken on during acquisition phases.

Latest Quarter Snapshot (Q1 2026)

The most recent data available — Q1 2026 (period ending March 31, 2026, filed May 7, 2026) — is more current than the annual figures and paints a positive picture heading into the new fiscal year. Gilead generated $6.96 billion in revenue for the quarter, with an operating margin of 37.2% and a net margin of 29.0%. EBITDA came in at $3.28 billion. Notably, the current ratio improved to 1.97, up from 1.55 at year-end 2025, suggesting a strengthening short-term liquidity position. The debt-to-equity ratio also declined to 0.94, the lowest level in the multi-year dataset, indicating continued balance sheet deleveraging. Capital expenditures for the quarter were $117 million (capex-to-revenue of 1.7%), consistent with the low capital-intensity profile seen across recent annual periods.

Profitability

Gilead's profitability history is marked by two distinct dips — 2020 and 2024 — both driven largely by non-cash impairment charges tied to acquisitions rather than fundamental deterioration in the operating business. In 2020, the net margin collapsed to just 0.5% following the Immunomedics acquisition write-downs. In 2024, a similar pattern emerged: despite revenue growing to $28.75 billion, the net margin fell to just 1.7% and EBITDA cratered to $4.44 billion, almost certainly reflecting large impairment charges. Stripping those out, the underlying business has consistently generated operating margins in the mid-to-high 20s and above.

The 2025 rebound is notable and arguably shows the true earnings power of the business: operating margin recovered to 34.0% and net margin to 28.9% — among the best results in the past five years. The Q1 2026 data suggests this recovery is continuing rather than fading. Gross margin data was not available in the filings provided. The EBITDA trajectory from 2022 through 2025 ($9.5B → $10.3B → $4.4B → $12.8B) underscores how acquisition accounting can distort year-to-year comparisons, but the direction heading into 2026 is clearly upward.

Financial Health

Gilead's balance sheet has improved meaningfully over the past year. The debt-to-equity ratio peaked at 1.73 in 2020 and has trended down since, reaching 1.10 in 2025 and a fresh low of 0.94 in Q1 2026. This is a healthy leverage level for a large-cap pharma with predictable cash flows. The current ratio has also been gradually improving, sitting at 1.55 at end-2025 and rising to 1.97 in Q1 2026, suggesting comfortable near-term liquidity.

Capital Expenditures: Gilead is a remarkably light spender on physical capital, as one would expect from a drug developer whose primary assets are intellectual property and human capital rather than factories and equipment. Capital expenditures data was not available in the 10-K filings for fiscal years 2016 and 2017. For the years where it is available, capex has ranged from a high of $924 million (4.2% of revenue) in 2018 down to $523 million (1.8%) in 2024, with 2025 coming in at $563 million (1.9%). The Q1 2026 quarterly capex of $117 million annualizes to roughly $468 million, suggesting capital intensity may edge slightly lower still. This declining-to-stable capex trend confirms that Gilead does not need to reinvest heavily in physical infrastructure to maintain or grow its revenue base — a hallmark of a high-quality, asset-light pharmaceutical business.

Growth

Gilead's top-line growth in recent years has been steady but unspectacular, reflecting the maturity of its core HIV franchise and the gradual ramp of newer products in oncology and inflammation. The table below shows trailing revenue CAGRs calculated directly from the company's 10-K filings.

The 3-year CAGR of 2.6% and 5-year CAGR of 3.6% place Gilead firmly in the "slow and steady" growth category for a large pharmaceutical company. The slightly higher 5-year figure reflects the favorable base effect of the relatively weak 2020 revenue year. Neither number signals a high-growth story, but in the context of a business generating ~$29 billion in annual revenue with 30%+ margins and modest capital requirements, low-single-digit revenue growth still translates into substantial free cash flow — which Gilead has historically returned to shareholders through dividends and buybacks while also funding its pipeline expansion.

Source Filings

• 10-Q filed 2026-05-07 (period ending March 31, 2026)
• 10-K filed 2026-02-24 (fiscal year ending December 31, 2025)